Citations

Showing 10 of 108152 citations.

30-Day Outcomes for Total Ankle Arthroplasty in Patients With Anemia
Pollock, Jordan R. , Doan, Matt K., Moore, M. Lane , Makovicka, Justin L. , Deckey, David G. , Kile, Todd A. , Hassebrock, Jeffrey D. , Moore, M Lane , Pollock, Jordan Riley , Doan, Matthew K. , Patel, Karan A.

Mayo Clinic

Foot & Ankle International | June 10, 2021 | Volume: 42 | Issue: 11 | Pages: 1463-1468

10.1177/10711007211017512 | PMID 34109838 Get It

Background: While anemia has been associated with poor surgical outcomes in total knee arthroplasty and total hip arthroplasty, the effects of anemia on total ankle arthroplasty remain unknown. This study examines how preoperative anemia affects postoperative outcomes in total ankle arthroplasty. Methods: A retrospective analysis was performed using the American College of Surgeons National Surgery Quality Improvement Project database from 2011 to 2018 for total ankle arthroplasty procedures. Hematocrit (HCT) levels were used to determine preoperative anemia. Results: Of the 1028 patients included in this study, 114 patients were found to be anemic. Univariate analysis demonstrated anemia was significantly associated with an increased average hospital length of stay (2.2 vs 1.8 days, P < .008), increased rate of 30-day readmission (3.5% vs 1.1%, P = .036), increased 30-day reoperation (2.6% vs 0.4%, P = .007), extended length of stay (64% vs 49.9%, P = .004), wound complication (1.75% vs 0.11%, P = .002), and surgical site infection (2.6% vs 0.6%, P = .017). Multivariate logistic regression analysis found anemia to be significantly associated with extended hospital length of stay (odds ratio [OR], 1.62; 95% CI, 1.07-2.45; P = .023) and increased reoperation rates (OR, 5.47; 95% CI, 1.15-26.00; P = .033). Anemia was not found to be a predictor of increased readmission rates (OR, 3.13; 95% CI, 0.93-10.56; P = .066) or postoperative complications (OR, 1.27; 95% CI, 0.35-4.56; P = .71). Conclusion: This study found increasing severity of anemia to be associated with extended hospital length of stay and increased reoperation rates. Providers and patients should be aware of the increased risks of total ankle arthroplasty with preoperative anemia. Level of Evidence: Level III, retrospective comparative study.
Electronic Cigarette Use Is Not Associated with COVID-19 Diagnosis
Jose, Thulasee , Croghan, Ivana T. , Schroeder, Darrell R. , Hays, J. Taylor , Jose, Thulasee , Schroeder, Darrell , Warner, David O.

Mayo Clinic

Journal of Primary Care & Community Health | June 10, 2021 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/21501327211024391 | PMID 34109870 Get It

This analysis tested the hypothesis that current e-cigarette use was associated with an increased risk of SARS-CoV-2 infection in patients seeking medical care. E-cigarette and conventional cigarette use were ascertained using a novel electronic health record tool, and COVID-19 diagnosis was ascertained by a validated institutional registry. Logistic regression models were fit to assess whether current e-cigarette use was associated with an increased risk of COVID-19 diagnosis. A total of 69,264 patients who were over the age of 12 years, smoked cigarettes or vaped, and were sought medical care at Mayo Clinic between September 15, 2019 and November 30, 2020 were included. The average age was 51.5 years, 62.1% were females and 86.3% were white; 11.1% were currently smoking cigarettes or using e-cigarettes and 5.1% tested positive for SARS-CoV-2. Patients who used only e-cigarettes were not more likely to have a COVID-19 diagnosis (OR 0.93 [0.69-1.25], P = .628), whereas those who used only cigarettes had a decreased risk (OR 0.43 [0.35-0.53], P < .001). The OR for dual users fell between these 2 values (OR 0.67 [0.49-0.92], P = .013). Although e-cigarettes have the well-documented potential for harm, they do not appear to increase susceptibility to SARS-CoV-2 infection. This result suggests the hypothesis that any beneficial effects of conventional cigarette smoking on susceptibility are not mediated by nicotine.
Comparative Evaluation of the VERSANT HCV RNA 3.0, QUANTIPLEX HCV RNA 2.0, and COBAS AMPLICOR HCV MONITOR Version 2.0 Assays for Quantification of Hepatitis C Virus RNA in Serum
Germer, Jeffrey J., Heimgartner, Paul J., Ilstrup, Duane M., Harmsen, William S. , Jenkins, G. Douglas , Patel, Robin

Mayo Clinic

Journal of Clinical Microbiology | June 10, 2021 | Volume: 40 | Issue: 5 | Pages: 1885-1885

10.1128/jcm.40.5.1885-1885a.2002 Get It

Comparison of Early Versus Late Initiation of Hydrocortisone in Patients With Septic Shock in the ICU Setting
Ragoonanan, David , Cannon, Chad , Rottman-Pietrzak, Kathleen, Bello, Abdel, Allen, Bryan, Cannon, Chad

Mayo Clinic

Annals of Pharmacotherapy | June 10, 2021 | Volume: 56 | Issue: 3 | Pages: 264-270

10.1177/10600280211021103 | PMID 34109850 Get It

Background: Multiple publications demonstrate an association between time to initiation of corticosteroids and outcomes such as mortality and reversal of shock. However, the optimal time to initiate hydrocortisone remains unknown. Objective: To evaluate the impact of early versus late initiation of hydrocortisone in septic shock patients. Methods: A retrospective, multicentered, observational study was conducted. Adults admitted from July 1, 2014, to August 31, 2019, diagnosed with septic shock receiving vasopressors and low-dose hydrocortisone were evaluated. Participants were divided into the “early” group if hydrocortisone was initiated within 12 hours or “late” group if initiated after 12 hours of vasopressor initiation. The primary outcome was time to vasopressor discontinuation. Secondary outcomes included in-hospital mortality, intensive care unit (ICU) and hospital length of stay (LOS), vasopressor utilization, fluids administered, and need for renal replacement therapy. Results: A total of 198 patients were identified for inclusion in this propensity score–weighted cohort: 99 in the early group and 99 in the late group. Early initiation was associated with shorter time to vasopressor discontinuation compared with late initiation (40.7 vs 60.6 hours; P = 0.0002). There was also a reduction in ICU LOS (3.6 vs 5.1 days; P = 0.0147) and hospital LOS (8.9 vs 10.9 days; P = 0.0220) seen in the early group. There was no difference in mortality between groups. Conclusion and Relevance: In this propensity-matched cohort, administration of hydrocortisone within 12 hours from the onset of septic shock was associated with improved time to vasopressor discontinuation and reduced ICU and hospital LOS.
Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients
Yetmar, Zachary A. , Beam, Elena , Ganesh, Ravindra , Bierle, Dennis M. , Brumble, Lisa , Seville, Maria Teresa , Razonable, Raymund R. , O'Horo, John C, Ganesh, Ravindra , Brumble, Lisa M , Razonable, Raymund R , Yetmar, Zachary A , Beam, Elena , O’Horo, John C.

Mayo Clinic

Open Forum Infectious Diseases | June 10, 2021 | Volume: 8 | Issue: 6 | Pages: No page available

10.1093/ofid/ofab255 | PMID 34631921 Get It

AbstractBackgroundBamlanivimab and casirivimab-imdevimab are authorized for emergency use treatment of mild to moderate coronavirus disease 2019 (COVID-19) in patients at high risk for developing severe disease or hospitalization. Their safety and efficacy have not been specifically evaluated in solid organ transplant recipients.MethodsWe retrospectively reviewed solid organ transplant recipients who received monoclonal antibody infusion for COVID-19 at Mayo Clinic sites through January 23, 2021. Outcomes included emergency department visit, hospitalization, mortality, and allograft rejection.ResultsSeventy-three patients were treated, most commonly with bamlanivimab (75.3%). The median age was 59 years, 63% were male, and the median Charlson comorbidity index was 5. Transplant type included 41 kidney (56.2%), 13 liver (17.8%), 11 heart (15.1%), 4 kidney-pancreas (5.5%), 2 lung (2.7%), 1 heart-liver, and 1 pancreas. Eleven (15.1%) patients had an emergency department visit within 28 days of infusion, including 9 (12.3%) who were hospitalized for a median of 4 days. One patient required intensive care unit admission for a nonrespiratory complication. No patients required mechanical ventilation, died, or experienced rejection. Ten adverse events occurred, with 1 seeking medical evaluation. Hypertension was associated with hospital admission (P &lt; .05), while other baseline characteristics were similar. The median time from symptom onset to antibody administration was 4 days in nonhospitalized patients compared with 6 days among hospitalized patients (P &lt; .05).ConclusionsMonoclonal antibody treatment has favorable outcomes with minimal adverse effects in solid organ transplant recipients with mild to moderate COVID-19. Earlier administration of monoclonal antibody therapy appears to be more efficacious.
Evidence-Based Recommendations for Opioid Prescribing After Endourological and Minimally Invasive Urological Surgery
Koo, Kevin , Patel, Hiten D. , Faisal, Farzana A., Gupta, Natasha , Metcalf, Meredith , Mettee, Lynda Z., Meyer, Alexa, Matlaga, Brian R., Group, for the Promoting Opioid Stewardship in Endourology Work, Winoker, Jared S. , Pavlovich, Christian P. , Pierorazio, Phillip , Group, for the Promoting Opioid Stewardship in Endourology Work

Mayo Clinic

Journal of Endourology | June 10, 2021 | Volume: 35 | Issue: 12 | Pages: 1838-1843

10.1089/end.2021.0250 | PMID 34107778 Get It

Association between Visceral Adipose Tissue and Non-Alcoholic Steatohepatitis Histology in Patients with Known or Suspected Non-Alcoholic Fatty Liver Disease
Idılman, Ilkay S. , Low, Hsien Min , Gidener, Tolga , Philbrick, Kenneth A. , Mounajjed, Taofic, Li, Jiahui , Yin, Meng , Venkatesh, Sudhakar K. , Philbrick, Kenneth, Venkatesh, Sudhakar K , Yin, Meng , Gidener, Tolga , Li, Jiahui , Allen, Alina M.

Mayo Clinic

Journal of Clinical Medicine | June 9, 2021 | Volume: 10 | Issue: 12 | Pages: 2565

10.3390/jcm10122565 | PMID 34200525 Get It

(1) Purpose: To determine the association between visceral adipose tissue (VAT) and proton density fat fraction (PDFF) with magnetic resonance imaging (MRI), and hepatic steatosis (HS), non-alcoholic steatohepatitis (NASH) and hepatic fibrosis (HF) in patients with known or suspected non-alcoholic fatty liver disease (NAFLD). (2) Methods: 135 subjects that had a liver biopsy performed within 3 months (bariatric cohort) or 1 month (NAFLD cohort) of an MRI exam formed the study group. VAT volume was quantified at L2-L3 level on opposed-phase images with signal intensity-based painting using a semi-quantitative software. Liver PDFF and pancreas PDFF were calculated on fat fraction maps. Liver volume (Lvol) and spleen volume (Svol) were also calculated using a semi-automated 3D volume tool available on PACS. A histological analysis was performed by an expert hepatopathologist blinded to imaging findings. (3) Results: The mean Lvol, Svol, liver PDFF, pancreas PDFF and VAT of the study population were 2492.2 mL, 381.6 mL, 13.2%, 12.7% and 120.6 mL, respectively. VAT showed moderate correlation with liver PDFF (r = 0.41, p < 0.001) and weak correlation with Lvol (r = 0.38, p < 0.001), Svol (r = 0.20, p = 0.025) and pancreas PDFF (rs = 0.29, p = 0.001). VAT, Lvol and liver PDFF were significantly higher in patients with HS (p < 0.001), NASH (p < 0.05) and HF (p < 0.05). VAT was also significantly higher in the presence of lobular inflammation (p = 0.019) and hepatocyte ballooning (p = 0.001). The cut-off VAT volumes for predicting HS, NASH and HF were 101.8 mL (AUC, 0.7), 111.8 mL (AUC, 0.64) and 111.6 mL (AUC, 0.66), respectively. (4) Conclusion: The MRI determined VAT can be used for predicting the presence of HS, NASH and HF in patients with known or suspected NAFLD.
Activation of c-fos Gene Expression by a Kinase-Deficient Epidermal Growth Factor Receptor
Eldredge, Emelyn R., Korf, Gina M., Christensen, Trace , Getz, Michael J., Maihle, Nita J. , Connolly, Denise C.

Mayo Clinic

Molecular and Cellular Biology | June 9, 2021 | Volume: 14 | Issue: 11 | Pages: 7527-7534

10.1128/mcb.14.11.7527-7534.1994 | PMID 7935468 Get It

Fear Avoidance Beliefs Are Associated With Perceived Disability in Persons With Vestibular Disorders
Dunlap, Pamela M. , Marchetti, Gregory F., Furman, Joseph M. , Delitto, Anthony , Klatt, Brooke N. , Whitney, Susan L. , Sparto, Patrick J. , Staab, Jeffrey P.

Mayo Clinic

Physical Therapy | June 9, 2021 | Volume: 101 | Issue: 9 | Pages: No page available

10.1093/ptj/pzab147 | PMID 34120180 Get It

Abstract Objective The purpose of this study was to determine the association between fear-avoidance beliefs and disability in 3 months in people with vestibular disorders while accounting for demographic and clinical characteristics. Methods This prospective cohort study included people aged 18 to 100 years who reported dizziness. Participants were recruited from a balance disorders clinic and outpatient physical therapy clinics. All participants completed the Vestibular Activities Avoidance Instrument (VAAI) and the Hospital Anxiety and Depression Scale at baseline and the Vestibular Activities and Participation measure (VAP), dizziness Visual Analogue Scale (VAS), and 12-item Short Form Health Questionnaire at baseline and 3-month follow-up. A modified version of the VAAI included 9 items abstracted from the 81-item VAAI. The relationships between 9-item VAAI scores and follow-up measures of disability were assessed using Spearman correlation coefficients. Linear regression models were analyzed to determine the effect of fear-avoidance beliefs on follow-up VAP score while accounting for baseline outcome measures. Results All participants (n = 404) completed the baseline assessment (mean age = 54 years), and 286 (71%) completed the 3-month assessment. The mean 9-item VAAI score was 25 (SD = 14) at baseline and was significantly associated with VAP (ρ = 0.54), 12-item Short Form Health Questionnaire component scores (ρ = −0.53; −0.44), and dizziness VAS at follow-up (ρ = 0.37). Approximately 38% of the variation in VAP score at follow-up was predicted by age, number of medications, 9-item VAAI score, dizziness VAS, and Hospital Anxiety and Depression Scale-depression score when considered together (R2 = 0.38). Conclusion Fear-avoidance beliefs are associated with measures of disability at 3 months and are predictive of activity limitations and participation restrictions at 3 months when controlling for age, medications, baseline dizziness, and depression symptom severity in people with vestibular disorders. Impact Measurement of fear-avoidance beliefs may provide important prognostic information, suggesting that an assessment of fear-avoidance beliefs could be used by clinicians to identify individuals at greater risk of disability after a vestibular disorder. Lay Summary Fear-avoidance beliefs in people who have vestibular disorders are associated with disability at 3 months and predict limitations in daily activities at 3 months.